IJSR International Journal of Scientific Research 2277 - 8179 Indian Society for Health and Advanced Research ijsr-7-4-15108 Original Research Paper COGNITIVE REHABILITATION IN PEDIATRIC COGNITIVE DISORDERS Moses. P. Moorthy Dr. Prof. K. Bhanu Dr. April 2018 7 4 01 02 ABSTRACT

AIM:

            L–Carnosine is an aminoacid, acts as a neuroprotective agent. Hence we studied the role of L – Carnosine in rehabilitation of pediatric cognitive disorders.

METHODS:

            This is a double blind placebo controlled study done in pediatric neurology division of Govt Mohan Kumaramangalam Medical College, Salem from January 2016 to December 2017.

            Children presented with cognition disorders due to autistic spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), cerebral palsy (CP), epilepsy and dyslexia were included.

            L–Carnosine is given as liquid form in the dose of 10–15mg/kg from 3–12 years of children presented with ASD, ADHD, CP, Epilepsy, and Dyslexia for 10 weeks.

Placebo children were treated with multivitamin supplement for period of 10 weeks, monitored and compared with children on L–Carnosine therapy.

Results:

            In this study 300 children were studied. L–Carnosine therapy (n=150), placebo therapy (n=150) male children (70%) mean age (7.1years). Female children (30%) mean age (8years) children on placebo therapy didn’t so statistically significant changes in cognitive outcome. Children on L–Carnosine therapy showed statistically significant improvement in cognition in ASD (p<0.00001), ADHD (p<0.00001), CP (p<0.0001), Epilepsy (P<0.00001) and Dyslexia (P<0.00001). Language domains, social communications, memory, behavior, learning ability showed statistically significant improvement. Gross motor ability also showed improvement and treatment of associated co–illness with anti–psychotics, CNS Psycho stimulants gives good clinical outcome.

Conclusion:

            L–Carnosine acts as neuroprotector; therapy shows statistically significant improvement in cognitive function in pediatric cognitive disorders when compared with placebo therapy.